These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 1689677)

  • 21. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?
    Tarle M; Kraljić I
    Anticancer Res; 1997; 17(3A):1531-4. PubMed ID: 9179191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
    Tsuchiya N; Ohyama C; Habuchi T
    Gan To Kagaku Ryoho; 2005 Feb; 32(2):275-80. PubMed ID: 15751649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate cancer-associated markers.
    Chu TM
    Immunol Ser; 1990; 53():339-56. PubMed ID: 1713065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prostate-specific antigen. A new biological serum marker for prostatic adenocarcinoma].
    Haukaas S; Skaarland E; Halvorsen OJ; Stensland E; Farstad M
    Tidsskr Nor Laegeforen; 1990 Sep; 110(23):2990-3. PubMed ID: 1700496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-specific antigen: a valuable clinical tool.
    Oesterling JE
    Oncology (Williston Park); 1991 Apr; 5(4):107-22; discussion 122, 125-6, 128. PubMed ID: 1714288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Tumor markers in prostate cancer].
    Kuriyama M
    Gan To Kagaku Ryoho; 1994 Sep; 21(12):1915-22. PubMed ID: 7521999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate specific antigen: clinical use in the diagnosis and management of prostate cancer.
    Kabalin JN
    Geriatrics; 1992 Sep; 47(9):26-32. PubMed ID: 1380941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
    Tarle M
    Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Role of prostate-specific antigen in prostatic carcinoma. Validity of an integrated methodologic approach and morpho-biological correlations].
    Tomasino RM; Lo Bianco A; Cacciatore M; Pavone C; Carreca I; Morello V; Salvato M; Florena AM; Pavone-Macaluso M
    Pathologica; 1989; 81(1072):109-26. PubMed ID: 2475847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
    Mikolajczyk SD; Rittenhouse HG
    Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
    Akdaş A; Simşek F; Ilker Y; Türkeri L; Ercan H
    Int Urol Nephrol; 1993; 25(3):271-8. PubMed ID: 7693607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detecting prostate cancer by intracellular macrophage prostate-specific antigen (PSA): a more specific and sensitive marker than conventional serum total PSA.
    Herwig R; Mitteregger D; Djavan B; Kramer G; Margreiter M; Leers MP; Glodny B; Haider DG; Hörl WH; Marberger M
    Eur J Clin Invest; 2008 Jun; 38(6):430-7. PubMed ID: 18489403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PSA excess in the differential diagnosis of prostate carcinoma.
    Díaz F; Morell M; Rojo G
    Arch Esp Urol; 1997 May; 50(4):415-8. PubMed ID: 9219422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy of serum prostate specific antigen as a tumour marker in prostatic carcinoma: a comparison with serum acid phosphatase.
    Cooke RR; Nacey JN; Beeston RE; Delahunt B
    N Z Med J; 1992 Sep; 105(941):345-7. PubMed ID: 1279493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Diagnostic value of prostatic specific antigen (PSA) in comparison to prostatic acid phosphatase (PAP) in prostatic cancer and adenoma].
    Dutkiewicz S; Stepień K; Witeska A
    Wiad Lek; 1992 Oct; 45(19-20):750-3. PubMed ID: 1284261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prostate-specific antigen in prostatic pathology].
    Teillac P; Peyret C; Leroy M; Najean Y; Le Duc A
    Ann Urol (Paris); 1988; 22(3):193-6. PubMed ID: 2456712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarkers for prostate cancer.
    Leman ES; Getzenberg RH
    J Cell Biochem; 2009 Sep; 108(1):3-9. PubMed ID: 19507229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate-specific antigen and prostate-specific acid phosphatase in neuroendocrine cells of prostate cancer.
    Cohen RJ; Glezerson G; Haffejee Z
    Arch Pathol Lab Med; 1992 Jan; 116(1):65-6. PubMed ID: 1370878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.